ES2490915R1 - Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos - Google Patents

Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos Download PDF

Info

Publication number
ES2490915R1
ES2490915R1 ES201490028A ES201490028A ES2490915R1 ES 2490915 R1 ES2490915 R1 ES 2490915R1 ES 201490028 A ES201490028 A ES 201490028A ES 201490028 A ES201490028 A ES 201490028A ES 2490915 R1 ES2490915 R1 ES 2490915R1
Authority
ES
Spain
Prior art keywords
ltc
epitopes
lymphocyte
responses
type hypersensitivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201490028A
Other languages
English (en)
Other versions
ES2490915B1 (es
ES2490915A2 (es
Inventor
Christian Brander
Marta RUIZ RIOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
IrsiCaixa Institut de Recerca de la Sida
Esteve Pharmaceuticals SA
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
IrsiCaixa Institut de Recerca de la Sida
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, IrsiCaixa Institut de Recerca de la Sida, Laboratorios del Dr Esteve SA filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of ES2490915A2 publication Critical patent/ES2490915A2/es
Publication of ES2490915R1 publication Critical patent/ES2490915R1/es
Application granted granted Critical
Publication of ES2490915B1 publication Critical patent/ES2490915B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/02—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos.#La presente invención se refiere a un método in vivo para monitorizar las repuestas de linfocitos T citotóxicos (LTC) induciendo una reacción de hipersensibilidad de tipo retardado (DTH) usando epítopos de LTC definidos. Se refiere además a los epítopos y sus kits.
ES201490028A 2011-09-12 2012-09-12 Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos Expired - Fee Related ES2490915B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161533476P 2011-09-12 2011-09-12
US61/533,476 2011-09-12
PCT/EP2012/067794 WO2013037804A1 (en) 2011-09-12 2012-09-12 Method for monitoring cytotoxic t lymphocyte (ctl) responses by a delayed-type hypersensitivity reaction using defined ctl viral epitopes

Publications (3)

Publication Number Publication Date
ES2490915A2 ES2490915A2 (es) 2014-09-04
ES2490915R1 true ES2490915R1 (es) 2015-01-02
ES2490915B1 ES2490915B1 (es) 2015-09-17

Family

ID=46832400

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201490028A Expired - Fee Related ES2490915B1 (es) 2011-09-12 2012-09-12 Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos

Country Status (2)

Country Link
ES (1) ES2490915B1 (es)
WO (1) WO2013037804A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015033137A1 (en) 2013-09-04 2015-03-12 Imperial Innovations Limited Biological methods and materials for use therein
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
EP4019042A1 (en) * 2020-12-23 2022-06-29 De La Cuesta Roldán, Carlos Method for determining whether an immune response has occurred in subjects who have been infected with- or vaccinated against coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050423A2 (fr) * 1997-05-07 1998-11-12 Centre National De La Recherche Scientifique Analogues peptidiques et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050423A2 (fr) * 1997-05-07 1998-11-12 Centre National De La Recherche Scientifique Analogues peptidiques et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASJÖ B et al. "Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy" AIDS RESEARCH AND HUMAN RETROVIRUSES, 20021210 MARY ANN LIEBERT, US 10/12/2002 VOL: 18 No: 18 Pags: 1357 - 1365 ISSN 0889-2229 Doi: doi:10.1089/088922202320935438; todo el documento. *
FUHLBRIGGE ROBERT C et al. "Cutaneous lymphocyte-associated antigen is a specialized form of P-selection glycoprotein ligand-1 (PSGL-1) expressed on skin-homing T cells" Arthritis and Rheumatism Sept., 1997 00/09/1997 VOL: 40 No: 9 SUPPL. Pags: S74 ISSN 0004-3591; todo el documento. *
KRAN ANNE-MARTE B et al. "HLA- and dose-dependent immunogenicity of a peptide based HIV-1 immunotherapy candidate (Vacc-4x)" AIDS (Hagerstown) September 24, 2004 24/09/2004 VOL: 18 No: 14 Pags: 1875-1883 ISSN 0269-9370; todo el documento. *
todo el documento. *

Also Published As

Publication number Publication date
ES2490915B1 (es) 2015-09-17
WO2013037804A1 (en) 2013-03-21
ES2490915A2 (es) 2014-09-04

Similar Documents

Publication Publication Date Title
FR23C1046I2 (fr) Antigenes de pre-fusion f du vrs
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
UY34456A (es) Anticuerpos anti-il-36r
CL2014001073A1 (es) Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy.
CO6811881A2 (es) Surfactantes para la recuperación mejorada de petróleo
CO6950446A2 (es) Mecanismo y método de sellado para empalme de cable de bajada
BR112013032845A2 (pt) sugestões de texto para imagens
DK2989893T3 (da) Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde
CL2013000076A1 (es) Metodos para la preparacion de profarmacos de fosforamidato diastereomericamente puros.
EP2741957A4 (en) MULTI-SPEED PLANE WITH INTERCHANGEABLE MISSION MODULES
DK2766392T3 (da) Fremgangsmåde til oprensning af antistoffer
BR112013030422A2 (pt) método para produção de carvão vegetal
BR112014013034A2 (pt) método para produzir um anticorpo
CO6920298A2 (es) Método para cultivar caña de azucar
BR112014007784A2 (pt) dessanilização eletroquímica para recuperação de petróleo
CL2013002164A1 (es) Metodo para la obtencion de un insaponificable.
CL2014000593A1 (es) Metodo para mejorar los rendimientos de cultivos mediante la aplicacion de trehalosa
BR112013024934A2 (pt) aparelho de geração de 1-metilciclopropeno
BR112014011115A2 (pt) métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
CL2015000590A1 (es) Método para recuperar oro.
BRDI7105327S (pt) Configuração aplicada em estojo para peças de dominó
CO6801691A2 (es) Método para fabricar un endulcorante natural mejorado
ES2490915R1 (es) Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos
BR112014002753A2 (pt) método para produzir olefinas via metátese
CO6890113A2 (es) Métodos para aislar ácidos 4-cloro-2-fluoro-3-fenilborónicos sustituidos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2490915

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150917

FD2A Announcement of lapse in spain

Effective date: 20210915